Pya Yuriy, Mussayev Abdurashid, Novikova Svetlana, Bekbossynova Makhabbat, Alimbayev Serik, Khissamutdinov Nail, Kapyshev Timur, Kuanyshbek Aidyn, Lesbekov Timur
Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Front Cardiovasc Med. 2023 Apr 6;10:1091420. doi: 10.3389/fcvm.2023.1091420. eCollection 2023.
The implantation of a left ventricular assist device (LVAD) has become an essential requirement for managing patients with end-stage heart failure. However, aortic valve insufficiency is a contraindication for LVAD implantation in patients with end-stage heart failure, partly because of the decreasing efficiency of mechanical circulatory support and the eventual development of right ventricular failure. Herein, we present the first case of performing transcatheter aortic valve replacement in valve-in-ring along with LVAD implantation for the treatment of a 60-year-old male suffering from refractory heart failure due to dilated cardiomyopathy and pure aortic insufficiency in need of a new aortic bioprosthesis. A balloon-expandable bioprosthetic transcatheter heart valve was implanted into a previously sewn annulus ring into the aortic root transaortic access. Subsequently, a centrifugal-flow LVAD was implanted. Postoperatively, the patient was in New York Heart Association Functional Class (NYHA) II with 6-min walk test of 310 m. The patient has completed 6 months of follow-up with no events. This novel and feasible surgical technique reduced the cardiopulmonary bypass time and duration of surgery. Furthermore, it avoids the risk of redo sternotomy and decreases the chances of paravalvular leakage and worsening of aortic regurgitation.
植入左心室辅助装置(LVAD)已成为治疗终末期心力衰竭患者的一项基本要求。然而,主动脉瓣关闭不全是终末期心力衰竭患者植入LVAD的禁忌症,部分原因是机械循环支持效率降低以及最终发生右心室衰竭。在此,我们报告首例在瓣中瓣植入经导管主动脉瓣置换术并同时植入LVAD,用于治疗一名60岁男性,该患者因扩张型心肌病和单纯主动脉瓣关闭不全导致难治性心力衰竭,需要植入新的主动脉生物假体。通过经主动脉途径将球囊扩张式生物假体经导管心脏瓣膜植入预先缝合在主动脉根部的瓣环中。随后,植入离心式LVAD。术后,患者处于纽约心脏协会功能分级(NYHA)II级,6分钟步行试验为310米。患者已完成6个月的随访,无不良事件发生。这种新颖且可行的手术技术缩短了体外循环时间和手术时长。此外,它避免了再次开胸的风险,并降低了瓣周漏和主动脉反流恶化的几率。